FGF-401 is an inhibitor of FGFR4 extracted from patent WO2015059668A1, compound example 83; has an IC50 of 1.9 nM.
CAS：1708971-55-4
分子式：C25H30N8O4
分子量：506.56
纯度：98%
存储：Store at -20°C

Background:

Roblitinib (FGF-401; Compound Example 83) is a highly selective and potent FGFR4 inhibitor with an IC50 of 1.9 nM[1]. Roblitinib has antitumor activity[2].

Roblitinib (FGF-401) inhibits growth of HCC and gastric cancer cell lines expressing FG19, FGFR4, and βklotho, and induces tumor regression in triple positive xenografts[2].

参考文献:
[1]. Nicole Buschmann, et al. Ring-fused bicyclic pyridyl derivatives as fgfr4 inhibitors. WO2015059668A1.
[2]. Hierro C, et al. Fibroblast Growth Factor (FGF) Receptor/FGF Inhibitors: Novel Targets and Strategies for Optimization of Response of Solid Tumors. Semin Oncol. 2015 Dec;42(6):801-19.